Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization.
Saved in:
| Title: | Optimizing immunogenicity and product presentation of a SARS-CoV-2 subunit vaccine composition: effects of delivery route, heterologous regimens with self-amplifying RNA vaccines, and lyophilization. |
|---|---|
| Authors: | Lykins WR; Access to Advanced Health Institute, Seattle, WA, United States., Pollet J; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., White JA; PATH, Seattle, WA, United States., Keegan B; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., Versteeg L; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., Strych U; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., Chen WH; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., Mohamath R; Access to Advanced Health Institute, Seattle, WA, United States., Ramer-Denisoff G; Access to Advanced Health Institute, Seattle, WA, United States., Reed S; Access to Advanced Health Institute, Seattle, WA, United States., Renshaw C; Access to Advanced Health Institute, Seattle, WA, United States., Beaver S; Access to Advanced Health Institute, Seattle, WA, United States., Gerhardt A; Access to Advanced Health Institute, Seattle, WA, United States., Voigt EA; Access to Advanced Health Institute, Seattle, WA, United States., Tomai MA; 3M Health Care, St. Paul, MN, United States., Sitrin R; PATH, Seattle, WA, United States., Choy RKM; PATH, Seattle, WA, United States., Cassels FJ; PATH, Seattle, WA, United States., Hotez PJ; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States.; Department of Biology, Baylor University, Waco, TX, United States., Bottazzi ME; Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, United States.; Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States., Fox CB; Access to Advanced Health Institute, Seattle, WA, United States.; Department of Global Health, University of Washington, Seattle, WA, United States. |
| Source: | Frontiers in immunology [Front Immunol] 2024 Dec 16; Vol. 15, pp. 1480976. Date of Electronic Publication: 2024 Dec 16 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1480976 |
